Sam Dagogo-Jack

Oct 31, 2024 | healio.com | Scott Buzby |Richard Smith |Sam Dagogo-Jack

You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Behavioral modification for obesity treatment produced results similar to pharmaceutical or surgical interventions. Patient behaviors for long-term weight management can determine who will best respond.

Aug 8, 2023 | jamanetwork.com | Sam Dagogo-Jack |Justin B. Echouffo-Tcheugui |Leigh Perreault |Linong Ji

In Reply In his Letter about our recent Review article,1 Dr Entezari-Maleki suggests that SGLT2 inhibitors be considered in the treatment of prediabetes while noting that no drug treatment has yet been approved by the FDA for people with prediabetes. Clearly, the glucosuric effect of SGLT2 inhibitors decreases blood glucose levels in people with hyperglycemia. Additionally, the weight loss induced by SGLT2 inhibitors would be beneficial in people with prediabetes who have overweight or obesity.